>
>
Cash position enhanced by over $22 million due to private placement and exercise of warrants and options Dosing in third dose cohort of multiple ascending
Vancouver, British Columbia–(Newsfile Corp. – August 2, 2022) – NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a
VANCOUVER, British Columbia–(BUSINESS WIRE)–NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have
NervGen Pharma Grants Stock Options Vancouver, British Columbia–(Newsfile Corp. – July 15, 2022) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”),
NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors Vancouver, British Columbia–(Newsfile Corp. – July 14, 2022) – NervGen
NervGen Pharma Provides Update on Closing of Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British
NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia–(Newsfile
NervGen Pharma Grants Stock Options Vancouver, British Columbia–(Newsfile Corp. – May 31, 2022) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”),
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA) Panel discussion will focus on the
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results Safety Review
